AQST
Income statement / Annual
Last year (2024), Aquestive Therapeutics, Inc.'s total revenue was $57.56 M,
an increase of 13.80% from the previous year.
In 2024, Aquestive Therapeutics, Inc.'s net income was -$44.14 M.
See Aquestive Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$57.56 M |
$50.58 M |
$47.68 M |
$50.83 M |
$45.85 M |
$52.61 M |
$67.43 M |
$66.92 M |
$51.79 M |
| Cost of Revenue |
$17.87 M
|
$20.83 M
|
$19.39 M
|
$14.99 M
|
$12.96 M
|
$20.36 M
|
$20.99 M
|
$19.82 M
|
$16.38 M
|
| Gross Profit |
$39.69 M
|
$29.75 M
|
$28.29 M
|
$35.84 M
|
$32.89 M
|
$32.25 M
|
$46.44 M
|
$47.10 M
|
$35.41 M
|
| Gross Profit Ratio |
0.69
|
0.59
|
0.59
|
0.71
|
0.72
|
0.61
|
0.69
|
0.7
|
0.68
|
| Research and Development Expenses |
$20.28 M
|
$13.10 M
|
$17.48 M
|
$17.05 M
|
$19.89 M
|
$20.57 M
|
$23.11 M
|
$22.13 M
|
$15.45 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$72.26 M
|
$25.08 M
|
$20.80 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$50.18 M
|
$31.75 M
|
$52.88 M
|
$53.48 M
|
$55.89 M
|
$64.34 M
|
$72.26 M
|
$25.08 M
|
$20.80 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$5.00 K
|
$0.00
|
-$99.00 K
|
| Operating Expenses |
$70.46 M
|
$44.85 M
|
$70.36 M
|
$70.52 M
|
$75.78 M
|
$84.92 M
|
$95.38 M
|
$47.21 M
|
$36.25 M
|
| Cost And Expenses |
$88.33 M
|
$65.69 M
|
$89.75 M
|
$85.51 M
|
$88.74 M
|
$105.28 M
|
$116.36 M
|
$67.03 M
|
$52.63 M
|
| Interest Income |
$3.44 M
|
$16.32 M
|
$99.00 K
|
$423.00 K
|
$132.00 K
|
$636.00 K
|
$552.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$16.82 M
|
$7.46 M
|
$12.44 M
|
$22.46 M
|
$13.02 M
|
$9.32 M
|
$7.71 M
|
$7.71 M
|
$6.14 M
|
| Depreciation & Amortization |
$718.00 K
|
$1.35 M
|
$2.39 M
|
$2.96 M
|
$3.61 M
|
$3.05 M
|
$3.34 M
|
$3.80 M
|
$3.89 M
|
| EBITDA |
-$26.62 M |
$1.18 M |
-$39.58 M |
-$45.11 M |
-$39.15 M |
-$53.88 M |
-$50.33 M |
$2.57 M |
$2.95 M |
| EBITDA Ratio |
-0.46
|
0.02
|
-0.83
|
-0.89
|
-0.85
|
-1.02
|
-0.75
|
0.04
|
0.06
|
| Operating Income Ratio |
-0.53
|
-0.3
|
-0.88
|
-0.68
|
-0.94
|
-1
|
-0.73
|
-0
|
-0.02
|
| Total Other Income/Expenses Net |
-$13.38 M
|
$7.48 M
|
-$12.34 M
|
-$35.86 M
|
-$12.89 M
|
-$13.58 M
|
-$12.44 M
|
-$8.83 M
|
-$8.76 M
|
| Income Before Tax |
-$44.15 M
|
-$7.63 M
|
-$54.41 M
|
-$70.54 M
|
-$55.78 M
|
-$66.25 M
|
-$61.38 M
|
-$8.94 M
|
-$9.60 M
|
| Income Before Tax Ratio |
-0.77
|
-0.15
|
-1.14
|
-1.39
|
-1.22
|
-1.26
|
-0.91
|
-0.13
|
-0.19
|
| Income Tax Expense |
-$14.00 K
|
$245.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$44.14 M
|
-$7.87 M
|
-$54.41 M
|
-$70.54 M
|
-$55.78 M
|
-$66.25 M
|
-$61.38 M
|
-$8.94 M
|
-$9.60 M
|
| Net Income Ratio |
-0.77
|
-0.16
|
-1.14
|
-1.39
|
-1.22
|
-1.26
|
-0.91
|
-0.13
|
-0.19
|
| EPS |
-0.51 |
-0.13 |
-1.12 |
-1.85 |
-1.66 |
-2.87 |
-2.96 |
-0.45 |
-0.39 |
| EPS Diluted |
-0.51 |
-0.13 |
-1.12 |
-1.85 |
-1.66 |
-2.87 |
-2.96 |
-0.45 |
-0.39 |
| Weighted Average Shares Out |
$86.73 M
|
$61.26 M
|
$48.73 M
|
$38.08 M
|
$33.65 M
|
$25.36 M
|
$20.73 M
|
$20.00 M
|
$24.50 M
|
| Weighted Average Shares Out Diluted |
$86.73 M
|
$61.26 M
|
$48.73 M
|
$38.08 M
|
$33.65 M
|
$25.36 M
|
$20.73 M
|
$20.00 M
|
$24.50 M
|
| Link |
|
|
|
|
|
|
|
|
|
